Synthetic biology & cell therapy/France, United Kingdom, Canada
1,844 lupus patients screened, 54 severe, three treated
Screening 1,844 lupus patients found 54 with severe disease and three ultimately treated with CAR T-cells.
A French multicentre study screened 1,844 systemic lupus erythematosus patients across seven certified autoimmune disease reference centres over one year, applying the 2024 EBMT and international eligibility criteria. Fifty-four (2.9%) met severe disease criteria and three (0.16%) were ultimately treated with CAR T-cells; 49 were not selected for trials.
What happened
A French group spanning the Centre Hospitalier Universitaire de Dijon Bourgogne, Saint-Louis Hospital, the Centre Hospitalier Universitaire de Rennes, the Centre Hospitalier de Saint-Quentin and the reference network for autoimmune disease and cell therapy published in Cytotherapy a study that counts rather than cures.
Over one year, from February 2024 to February 2025, they screened patients at seven certified autoimmune disease reference centres.
All adult patients meeting the 2019 EULAR and American College of Rheumatology criteria for systemic lupus erythematosus were screened for disease activity and severity against the 2024 EBMT and International Society for Cell and Gene Therapy criteria.
1,844 patients were screened. 54 (2.9%) demonstrated severe disease criteria. Three (0.16%) were ultimately treated with CAR T-cells. Forty-nine met criteria but were not selected for CAR T-cell trials.
The test
The study design is simple and the choice of question is what makes it valuable.
Anti-CD19 CAR T-cell therapy has produced sustained remission in severe refractory lupus, and the published cases have been striking. In severe patients resistant to first- and second-line therapy, 10-year mortality remains around 10 to 15%, so the unmet need is real.
What nobody had established is how many patients the eligibility criteria actually identify in practice. That is an arithmetic question requiring a consecutive population and a defined criteria set, and this study supplies both: all adult lupus patients across seven certified reference centres, screened against the published 2024 criteria.
Reference centres are the relevant setting because they concentrate the severe patients. If the yield is low there, it is lower everywhere else.
The numbers
| Stage | Patients | Share of screened |
|---|---|---|
| Screened against EULAR/ACR 2019 criteria | 1,844 | 100% |
| Met 2024 EBMT / ISCT severe disease criteria | 54 | 2.9% |
| Met criteria but not selected for trials | 49 | 2.7% |
| Ultimately treated with CAR T-cells | 3 | 0.16% |
| Centres | 7 certified autoimmune disease reference centres | |
| Period | February 2024 to February 2025 | |
| 10-year mortality, severe resistant lupus | around 10 to 15% | |
The result
The funnel is the finding, and the shape of it is the point.
From 1,844 screened, 2.9% met severe disease criteria. From those 54, three were treated. That is 0.16% of the screened population, or roughly one patient in six hundred.
Two gaps produce that number. The first, from 1,844 to 54, is the criteria doing their job: most lupus is not severe refractory disease. The second, from 54 to three, is the interesting one. Forty-nine patients met the criteria and were not treated.
The abstract attributes this to patients not being selected for CAR T-cell trials, which bundles several very different reasons: trial slots, manufacturing capacity, additional trial-specific exclusions, patient choice and clinician judgement. Separating those would change what the number means. If the constraint is trial capacity, it will ease. If it is additional exclusions, it will not.
How this compares to what came before
The CAR T-cell literature in autoimmune disease has been built on case series and small trials reporting remission, and those reports are genuine. What they do not establish is reach.
This batch contains the complementary paper. A meta-analysis of 16 real-world studies covering 2,097 patients with myeloma found a pooled grade 3 to 4 infection rate of 24.2%, with 26% for bispecific antibodies and 19% for CAR T-cells. That study measures what happens to patients who receive these therapies; this one measures how many reach them.
Together they describe a therapy class that is both toxic and scarce. Neither finding appears in the remission reports, and both belong in any discussion of cell therapy becoming standard care.
The broader pattern across this batch is that the papers measuring access and implementation tell a harsher story than the papers measuring efficacy. The CAD4TB implementation assessment in Tanzania found a nationally registered AI tool running with no agreed threshold. A digital inclusion pilot had to go looking for the patients other trials exclude. This study counts three treated patients out of 1,844.
What it means
For clinicians, the practical reading is that CAR T-cell therapy for lupus is currently a referral to a trial for a very small number of patients, not an option to discuss routinely.
For health systems planning cell therapy capacity, the 2.9% severe-disease figure is the useful planning number, because that is the population that would be eligible if capacity existed. The 0.16% is the current reality, and the gap between them is the demand that will materialise as trials expand.
For the 49 patients who met criteria and were not treated, the clinical question is what they received instead, and the research question is why. That group is where the constraint lives.
Business ideas from this paper
Eligibility screening infrastructure for cell therapy across disease registries, automating the criteria application that this study did by hand across seven centres.
Capacity modelling for autoimmune cell therapy, using the 2.9% severe-disease rate against national lupus prevalence to size manufacturing and bed requirements.
Bridging therapy pathways for patients who meet severity criteria and cannot access cell therapy, which on these numbers is sixteen times more patients than those who can.
What could be wrong with it
The study is retrospective and covers one year in one country’s reference network, so it reflects the current state of trial availability as much as any intrinsic property of the criteria.
It measures eligibility, not outcomes. Whether the three treated patients benefited is not addressed.
The reasons the 49 eligible patients were not selected are not disaggregated in the record abstract, and they determine whether the bottleneck is structural or temporary.
Certified reference centres concentrate severe disease, so the 2.9% figure is an upper bound on severity prevalence rather than a population estimate.
No data availability statement appears in the indexed record.
The 10 to 15% ten-year mortality figure for severe resistant lupus is cited as background rather than measured in this cohort.
How sure can you be?
Confident in the funnel: 1,844 screened, 54 meeting severe disease criteria, three treated, across seven centres in one year.
Confident that the screening applied the 2024 EBMT and ISCT criteria to patients identified by the 2019 EULAR and ACR criteria, which are the relevant published standards.
Confident that 49 patients met severity criteria without receiving the therapy.
Less confident about why those 49 were not treated, which the record does not disaggregate.
Less confident that these proportions transfer to other countries with different trial access and reimbursement.
Not confident about anything concerning benefit, which is outside the study.
Our rubric places this in the upper part of the range for this batch: peer-reviewed, many institutions, a retrospective multicentre study across seven independent certified centres, and no public data deposit.
Do this today
When a therapy is described as transforming a disease, ask what share of screened patients receive it. Here it is 0.16%.
If you plan cell therapy capacity, use the 2.9% severe-disease figure rather than the treated figure. The first is demand; the second is current supply.
If you are researching access, the 49 patients who met criteria and were not treated are the group to study. That gap is where the constraint is.
Source: Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France, Cytotherapy, 2026-01-20. PMID 41775117 · doi.org ().
Just Out Tech explains new research in plain language. This article was drafted with AI assistance and checked by a human against the original source.
- One-year retrospective multicentre screening study, February 2024 to February 2025, across seven certified autoimmune disease reference centres.
- 1,844 systemic lupus erythematosus patients were screened against the 2024 EBMT and International Society for Cell and Gene Therapy criteria.
- 54 patients (2.9%) demonstrated severe disease criteria; three (0.16%) were ultimately treated with CAR T-cells.
- Forty-nine patients met criteria but were not selected for CAR T-cell trials; in severe treatment-resistant lupus the 10-year mortality remains around 10 to 15%.
One-year retrospective multicentre screening of consecutive patients against published international criteria across seven certified reference centres; no outcomes.
Questions people ask
Why does the funnel matter more than the remission reports?
Because a therapy that works spectacularly for a handful of patients and reaches 0.16% of a screened population is a different clinical proposition from one that is becoming standard care.
What happened to the 49?
They met the severity criteria but were not selected for CAR T-cell trials, for reasons the abstract only gestures at. That group is arguably the most interesting in the study.
Is this about criteria or about availability?
Both, and the study cannot fully separate them. Trial slots, manufacturing capacity and centre access all constrain who gets treated, independently of the written criteria.
Does the study report outcomes?
No. It measures eligibility. Whether the three treated patients did well is not its subject.